Ustekinumab-aekn NDC 51759-710

NDC codes

FDA NDC Directory

Product NDC (as listed)51759-710Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51759-0710Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51759-710-32	51759071032	1 TRAY in 1 CARTON (51759-710-32) / 1 SYRINGE, GLASS in 1 TRAY / 1 mL in 1 SYRINGE, GLASSMarketed from Jun 2, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ustekinumab-aekn
Generic name (nonproprietary): ustekinumab-aekn
Active ingredients: Ustekinumab-aekn — 90 mg/mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Teva Pharmaceuticals USA, Inc.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761343
Marketing start: Jun 2, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Interleukin-12 Antagonists (Mechanism)Interleukin-23 Antagonists (Mechanism)
Identifiers: Product ID 51759-710_567b4eb5-b40e-4ade-bbf9-3ec158c15537SPL ID 567b4eb5-b40e-4ade-bbf9-3ec158c15537SPL set ID 183a1dff-ef33-4ddb-ba38-f7861b0f77adRxCUI 2705393, 2705400UNII FU77B4U5Z0
Pharmacologic class: Interleukin-12 Antagonist; Interleukin-23 Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N451759071032 followed by a unit qualifier and the quantity

Package 51759-0710-32. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 30, 2026.

Indications (excerpt from the label)

Ustekinumab-aekn is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn’s disease (CD). ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) 1.1 Plaque Psoriasis (PsO) Ustekinumab-aekn is indicated for the treatment of adults and pediatric patients 6 years of age …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761343

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761343
Product	Strength	Form · route	Labeler	Product NDC
Ustekinumab-aekn	Ustekinumab-aekn 45 mg/.5mL	Injection, SolutionSubcutaneous	Teva Pharmaceuticals USA, Inc.	51759-413
Ustekinumab-aekn	Ustekinumab-aekn 90 mg/mL	Injection, SolutionSubcutaneous	Teva Pharmaceuticals USA, Inc.	51759-414
Selarsdiustekinumab-aekn	Ustekinumab-aekn 45 mg/.5mL	Injection, SolutionSubcutaneous	Teva Pharmaceuticals USA, Inc.	51759-505
Selarsdiustekinumab-aekn	Ustekinumab-aekn 130 mg/26mL	Injection, SolutionIntravenous	Teva Pharmaceuticals USA, Inc.	51759-708
Ustekinumab-aekn	Ustekinumab-aekn 45 mg/.5mL	Injection, SolutionSubcutaneous	Teva Pharmaceuticals USA, Inc.	51759-709
Selarsdiustekinumab-aekn	Ustekinumab 90 mg/mL	Injection, SolutionSubcutaneous	A-S Medication Solutions	50090-7769
Selarsdiustekinumab-aekn	Ustekinumab-aekn 90 mg/mL	Injection, SolutionSubcutaneous	Teva Pharmaceuticals USA, Inc.	51759-607